Boston Scientific BSX, a prominent global player in cardiovascular technology, is well-positioned to capitalize on the robust expansion of the cardiovascular devices market. According to a MarketsandMarkets report, this market was valued at $72.83 billion in 2023 and is expected to witness a strong CAGR of 7.3% between 2024 and 2029.
Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Here is how Boston Scientific (BSX) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.
22 Jul 2025 (42 Days) Date | | - Cons. EPS | - EPS |
22 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | - Cons. EPS | - EPS |
24 Oct 2024 Date | | - Cons. EPS | - EPS |
23 Oct 2024 Date | | - Cons. EPS | - EPS |
22 Jul 2025 (42 Days) Date | | - Cons. EPS | - EPS |
22 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | - Cons. EPS | - EPS |
24 Oct 2024 Date | | - Cons. EPS | - EPS |
23 Oct 2024 Date | | - Cons. EPS | - EPS |
Medical - Devices Industry | Healthcare Sector | Mr. Michael F. Mahoney CEO | XMUN Exchange | US1011371077 ISIN |
US Country | 53,000 Employees | - Last Dividend | 6 Nov 2003 Last Split | 18 May 1992 IPO Date |
Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices used in a variety of interventional medical specialties. Having begun its operations in 1979, the company has grown to serve a diverse range of medical needs through its two primary segments: MedSurg and Cardiovascular. With its headquarters in Marlborough, Massachusetts, Boston Scientific is committed to improving patient health by providing cutting-edge solutions that address complex medical conditions and enhance the quality of life for patients worldwide.